Streetbeat News

BIVI

BioVie Inc.

Industry

Biotechnology

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Open

3.35

Mkt cap

57M

Volume

2.4M

High

3.35

P/E Ratio

-0.44

52-wk high

58.20

Low

2.97

Div yield

N/A

52-wk low

1.04

BioVie Inc. has announced a registered direct offering and concurrent private placement, raising $6 million through the sale of 2.67 million shares at $2.25 per share. The company will issue unregistered warrants for additional shares, with proceeds intended for working capital and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 7:26 pm

Several health care stocks experienced significant price movements during Wednesday's intraday session. CNS Pharma, Virax Biolabs Group, and Tevogen Bio Holdings were among the top gainers, while Alto Neuroscience and Silexion Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:31 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. CNS Pharma, DBV Technologies, and Cyclacel Pharmaceuticals were among the top gainers, while Alto Neuroscience and Ensysce Biosciences saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 12:08 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. CNS Pharma, DBV Technologies, and Cyclacel Pharmaceuticals saw substantial gains, while Alto Neuroscience and Ensysce Biosciences faced notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 12:07 pm

BioVie shares are experiencing an increase in trading value following the successful closure of its registered direct offering and concurrent private placement.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:29 pm

BioVie has successfully closed a registered direct offering and a concurrent private placement, raising $6.66 million by issuing 4,443,000 shares at $1.50 per share.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:18 pm

Several healthcare stocks experienced significant price movements during Tuesday's intraday session. Ensysce Biosciences, ENDRA Life Sciences, and Genprex saw substantial gains, while IN8bio, GRI Bio, and Voyager Therapeutics faced notable declines.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 4:31 pm

iRhythm Technologies shares surged over 20% in pre-market trading following FDA clearance for its Zio AT device. Other notable pre-market movers include Genprex, SRM Entertainment, and TC Biopharm, with significant gains, while companies like IN8bio and DMC Global saw declines.

Portfolio Pulse from Avi Kapoor

October 22, 2024 | 11:06 am

BioVie shares have resumed trading after a halt. This development is significant for investors as it may impact the stock's short-term price movement.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 7:32 pm

BioVie shares experienced a trading halt after a significant upside movement, with the stock rising by 63.83%.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 7:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.